The dosing problem in women is a precision problem. Physiological female testosterone concentrations are a small fraction of male concentrations, so the window between a physiological dose and an inadvertently supraphysiological one is correspondingly narrow.
That is why the Global Consensus Position Statement on the Use of Testosterone Therapy for Women exists as its own document rather than as a footnote to the male guideline,[1] and why the randomised evidence was reviewed separately for this population.[2]
Why "divide the male dose" fails
It sounds arithmetically reasonable and it is not, for reasons that are practical rather than theoretical.
Delivery devices are not built for it. A pump or sachet metered for a male dose does not subdivide accurately. The precision of the device becomes the limiting factor on the precision of the dose.
Small absolute errors are large relative ones. When the target is a fraction of the male range, a delivery variation that is trivial for a man can be substantial for a woman.
Absorption varies. Transdermal delivery depends on application site, area and skin — variability that matters more when the target window is narrower.[3]
Why the transdermal route dominates the discussion
Because it avoids the liver. Oral testosterone is inactivated by first-pass hepatic metabolism, and the modified oral androgens that survive it carry hepatotoxicity concerns.[5] That constraint applies to women exactly as it does to men.
Which leaves transdermal delivery as the practical route — and transdermal delivery is a permeation problem, dependent on formulation and site.[3] For a population needing small, consistent doses, the engineering of the delivery system is not a detail; it is the therapy.
What the consensus provides, and what it doesn't
It provides an internationally agreed position on what testosterone therapy in women is supported for, grounded in the randomised evidence.[1][2]
It does not provide what the male guideline provides on the diagnostic side: a threshold defining deficiency. There is no such threshold in women — the subject of what low testosterone actually does to women.
And it cannot conjure an approved product where none exists, which leaves the practical gap described in the ISSWSH and FDA standoff.
Frequently asked questions
Can I just use a smaller amount of my partner's gel? No. Delivery devices are not built for accurate subdivision, and the transfer precautions on topical testosterone apply regardless — see gel transfer risk.
What dose is right for women? A clinical decision guided by the consensus statement, your situation and monitoring.[1] Not a number to self-select.
How is treatment monitored? Through symptoms and levels interpreted against the female physiological range — which requires an assay validated for that range.
Where is the clinical article rather than the history? Testosterone therapy for women, on the women's pillar.
Where the story goes next
Delivery precision is the thread that connects this season to the platform question — how you get a small, consistent transdermal dose at all. The remaining T Files seasons are in progress.
In the meantime: the published clinical evidence and the pharmacokinetic Goldilocks problem.
References
5 sources
- Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660–4666. doi:10.1210/jc.2019-01603 · PMID 31498871
- Islam RM, Bell RJ, Green S, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754–766. doi:10.1016/S2213-8587(19)30189-5 · PMID 31353194
- Hadgraft J, Lane ME. Transdermal delivery of testosterone. Eur J Pharm Biopharm. 2015;92:42–48. doi:10.1016/j.ejpb.2015.02.015 · PMID 25709060
- Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172–E1181. doi:10.1152/ajpendo.2001.281.6.E1172 · PMID 11701431
- Jockenhövel F. Testosterone supplementation: what and how to give. Aging Male. 2003;6(3):200–206. PMID 14628500
Practical questions about membership, labs and using the spray are answered in the Learn Hub FAQ.